Alk-abello A/s Class B · OMXCOP:ALK_B
Alk-abello A/s Class B — FY2022 Earnings Presentation
14 slides from Alk-abello A/s Class B's earnings presentation, Feb 3, 2023
Slide 1: Full-year 2022 presentation
Full-year 2022 presentation Webcast 3 February 2023
Slide 2: Today's agenda
2 Webcast 3 February 2023 Q4 2022 presentation Today’s agenda • Q4 highlights • Full-year highlights • Performance o Market & product trends o Financials • Strategic progress President & CEO EVP, Group CFO VP, Head of IR o North America Carsten Hellmann Søren Jelert Per Plotnikof o China o Paediatri
Slide 3: Q4: 12% growth across regions
3 Webcast 3 February 2023 Q4: 12% growth across regions Results in line with the most recent outlook • Record-high quarterly revenue of DKK 1,249m • Tablet sales up 14% despite weaking of AIT-market in Germany • Non-tablet sales up 10% led by SCIT and Jext® • EBITDA up to DKK 201m, driven by sales g
Slide 4: FY: Best-ever financial results
4 Webcast 3 February 2023 FY: Best-ever financial results Resilience despite macroeconomic challenges – on track for ’25 in 25’ • 13% organic sales growth (15% growth in DKK) • EBITDA up 33% on sales growth and operational leverage • Progress with strategic agenda, 300,000 additional patients • Furt
Slide 5: Growth in all sales regions
5 Webcast 3 February 2023 Growth in all sales regions Overall German AIT market weakened in H2 – ALK expanded market leadership Europe North America International markets Share of FY revenue Share of FY revenue Share of FY revenue 13% 19% 68% Q4 Q4 Q4 871m 226m 152m +10% +6% +36% 795m 193m 111m FY F
Slide 6: Portfolio-wide growth led by tablets and Jext
6 Webcast 3 February 2023 Portfolio-wide growth led by tablets and Jext® European SCIT sales rebounded in Q4 as venom products recovered from previous supply constraints Tablets SCIT/SLIT-drops Other products Share of FY revenue Share of FY revenue Share of FY revenue 15% 46% 39% Q4 Q4 Q4 581m 512m
Slide 7: Sales growth drives margin expansion
7 Webcast 3 February 2023 Sales growth drives margin expansion EBIT-margin at 10%, up 3 p.p. DKK million 2021 2022 Research & Development Costs Share of revenue Revenue 3,916 4,511 DKKm % 18 800 16 Gross profit 2,396 2,791 600 400 14 Gross margin 61% 62% DKK 30m one-offs 200 12 0 10 2018 2019 2020 2
Slide 8: Delivering on long-term strategy
8 Webcast 3 February 2023 Delivering on long-term strategy Key priorities Succeed in Complete & commercialise Consumer engagement Optimise for North America the tablet portfolio and new horizons excellence Double-digit growth Expansion: HDM tablet First read-outs from Upscale tablet production targe
Slide 9: Succeed in North America
9 Webcast 3 February 2023 Succeed in North America Adjustment of business model to succeed through new prescribers and sales channels USA – Legacy USA – Tablets Canada – Tablets Allergists Paediatricians Partnerships SCIT bulk extracts, Focus on region- Similar dynamics Focus on innovators Fully ind
Slide 10: Complete & commercialise the tablet portfolio
10 Webcast 3 February 2023 Complete & commercialise the tablet portfolio China to become the world’s largest market for house dust mite (HDM) AIT China: Strong market fundamentals China: ALK’s ramp-up in 2022 • ~100 million people affected by HDM allergy • 64% staff expansion: 133 FTEs in 4 cities •
Slide 11: Complete & commercialise the tablet portfolio
11 Webcast 3 February 2023 Complete & commercialise the tablet portfolio Full approval for young patients is a key priority – and an important future growth driver for ALK • Large-scale paediatric trials with HDM and tree pollen tablets to complete in 2023 • Subject to approval, tablets could be ava
Slide 12: 2023 outlook
12 Webcast 3 February 2023 2023 outlook ALK expects to continue its trajectory of growth and earnings improvements in 2023 Revenue Revenue 7-11% growth • Equals 8-12% organic growth when disregarding DKKm in local currencies one-year, mandatory rebate increase in Germany 5,000 • Broad-based growth i
Slide 13: Q&A session
Q&A session
Slide 14: Thank you for your attention
14 Webcast 3 February 2023 Thank you for your attention 6 February 2023: Roadshow Copenhagen 8 February 23: Virtual roadshow London 21 February 23: Roadshow Paris 22 February 23: Roadshow Switzerland 23 February 23: Roadshow Frankfurt Investor Relations: Per Plotnikof, Vice President, Head of Invest